An eye exam may be all that is needed to diagnose Parkinson's disease, new research shows. Using an advanced machine-learning algorithm and fundus eye images, which depict the small blood vessels and more at the back of the eye, investigators are able to classify patients with Parkinson's disease compared against a control group. Continue reading →

November 30, 2020 07:00 ET | Source: Anavex Life Sciences Corp. NEW YORK, Nov Continue reading →

() () URL() Peptron said that it has signed a licensing agreement with Harvard University to evaluate the efficacy of PT320, a treatment for Parkinson's disease, as a possible treatment candidate for Alzheimer's disease. "After receiving a request from Mclean Hospital Harvard Medical School to confirm the efficacy of Peptron's PT320 in Alzheimer's disease treatment with its animal model, the company has decided to license out the treatment candidate to the hospital," a company official said. "Harvard's animal model is an advanced nonclinical trial most compatible with Alzheimer's disease." The efficacy test is scheduled to begin next month, he added. Continue reading →

ACADIA Pharmaceuticals (Acadia) (ACAD) is a name which I have lost coverage on over the past few years, enough of a reason to provide an update. Continue reading →

Scientists from Trinity College Dublin have developed a new gene therapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study, which involved a collaboration with clinical teams in the Royal Victoria Eye and Ear Hospital and the Mater Hospital, also has implications for a much wider suite of neurological disorders associated with ageing. Continue reading →